High-dose chemotherapy with or without total body irradiation, followed by allogeneic or autologous bone marrow transplantation, is of demonstrated clinical utility in the treatment of a number of hematological malignancies, e.g. acute lymphoblastic leukemia and non-Hodgkin's lymphoma, as well as a few solid tumors, e.g. breast cancer. However, while remissions are readily achieved, complete success is limited by a dismally high relapse rate. Oxazaphosphorines are often used as part of these therapeutic strategies either in vivo (cyclophosphamide or ifosfamide) as part of the high-dose chemotherapy regimen (autologous and allogeneic BMT) and/or ex vivo (4-hydroperoxycyclophosphamide or mafosfamide) to purged bone marrow of malignant cells (autologous BMT). Potentially, several enzymes, especially some (but not all) aldehyde dehydrogenases, may act to catalyze the detoxification of the oxazaphosphorines in target malignant cells thus protecting such cells from the cytotoxic action of the drug. The overall objectives of the investigations described herein are to test the notions that inherent and/or acquired insensitivity to the oxazaphosphorines is a contributing factor to the high relapse rates, and that the biological basis for this insensitivity is a higher than usual level of aldehyde dehydrogenase-catalyzed detoxification of the oxazaphosphorines. Leukemic bone marrow samples and bone marrow or surgical lymph node specimens will be obtained from the oxazaphosphorine-naive and oxazaphosphorine-treated relapsed ALL and NHL patients, respectively, and a clonogenic assay will be used to quantify the sensitivity of these samples to mafosfamide. Aldehyde dehydrogenase-catalyzed oxidation of aldophosphamide to carboxyphosphamide by these samples will also be quantified. On-going studies designed to identify and characterize human aldehyde dehydrogenases that are relevant with regard to catalyzing the detoxification of oxazaphosphorines will be continued. Column chromatography and isoelectric focusing will be used to separate and semi-purify these enzymes. A spectrophotometric assay utilizing the substrate of interest, viz. aldophosphamide, will be used to kinetically characterize relevant enzymes. The possibility that other enzymes, e.g. aldehyde oxidase, aldehyde reductase and/or phosphoroamidases, mediate inherent and/or acquired insensitivity to the oxazaphosphorines will also be explored. Human tumor sublines that are highly resistant to the oxazaphosphorines and established in culture will be used for this purpose. The underlying molecular basis for any increased enzyme activity will be sought in all cases. Techniques common to molecular biology, vis, Western, Northern and Southern blots, will be used for this purpose. Ultimately, this information is expected to serve as the basis for the optimal therapeutic utilization of the oxazaphosphorines in BMT protocols.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
3P01CA021737-19S1
Application #
6236429
Study Section
Project Start
1996-01-01
Project End
1997-03-31
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
19
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
168559177
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Flynn, Catherine M; Hirsch, Betsy; Defor, Todd et al. (2007) Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis. Am J Hematol 82:867-72
Orchard, Paul J; Blazar, Bruce R; Wagner, John et al. (2007) Hematopoietic cell therapy for metabolic disease. J Pediatr 151:340-6
Grewal, Satkiran S; Barker, Juliet N; Davies, Stella M et al. (2003) Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood? Blood 101:4233-44
Wagner, John E; Barker, Juliet N; DeFor, Todd E et al. (2002) Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 100:1611-8
Sladek, Norman E (2002) Leukemic cell insensitivity to cyclophosphamide and other oxazaphosphorines mediated by aldehyde dehydrogenase(s). Cancer Treat Res 112:161-75
Browne, P V; Weisdorf, D J; DeFor, T et al. (2000) Response to thalidomide therapy in refractory chronic graft-versus-host disease. Bone Marrow Transplant 26:865-9
Delforge, M; Boogaerts, M A; McGlave, P B et al. (1999) BCR/ABL- CD34(+)HLA-DR- progenitor cells in early chronic phase, but not in more advanced phases, of chronic myelogenous leukemia are polyclonal. Blood 93:284-92
Verfaillie, C M; Bhatia, R; Steinbuch, M et al. (1998) Comparative analysis of autografting in chronic myelogenous leukemia: effects of priming regimen and marrow or blood origin of stem cells. Blood 92:1820-31
Orchard, P J; Miller, J S; McGlennen, R et al. (1998) Graft-versus-leukemia is sufficient to induce remission in juvenile myelomonocytic leukemia. Bone Marrow Transplant 22:201-3
Erice, A; Borrell, N; Li, W et al. (1998) Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis. J Infect Dis 178:531-4

Showing the most recent 10 out of 416 publications